Veracyte accepts all third-party insurance, including Medicare and Medicaid. The Envisia test is covered by Medicare with no co-payment. Patients with private insurance or that are uninsured and that have financial need may apply for reimbursement support through the Veracyte Access Program. The Envisia Genomic Classifier is available to cash-pay patients without financial need at the price of $5,500.00. For questions, please contact a Veracyte Client Services representative at 844.464.LUNG (5864) or email@example.com.